In conclusion, TTK, NEK2, and CDK1 are strongly associated with tumorigenesis, therapeutic resistance, and poor prognosis of ovarian carcinoma and thus serve as a novel biomarker for diagnosis as well as attractive therapeutic targets for the treatment of ovarian carcinoma. This evidence concerns the gene CDK1 and ovarian carcinoma.